UB003

UB003 is an investigational small molecule drug candidate being developed by U-Neuron Biomedical, a Taiwanese biotechnology company, for the treatment of moderate to severe dry eye syndrome. Formulated as a topical ophthalmic solution, UB003 is designed to address the underlying pathology of dry eye disease, which often involves ocular surface inflammation and corneal nerve damage. The drug is part of U-Neuron's specialized pipeline focused on neuro-regenerative medicine, suggesting a mechanism of action that may involve the restoration or protection of corneal nerves to improve tear film stability and ocular surface health. UB003 is currently in the early stages of clinical development, following a timeline that targets potential commercialization or advanced clinical milestones by 2027.